Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

aMVAC.P_001_TURBT_S217

efdff87a-2c8d-5096-bffc-b1b72acd4af1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.350
  • ADIPOGENESIS+0.220
  • PEROXISOME+0.200
  • BILE_ACID_METABOLISM+0.190
  • CHOLESTEROL_HOMEOSTASIS+0.140
  • UNFOLDED_PROTEIN_RESPONSE+0.140
  • ANDROGEN_RESPONSE+0.100
  • ESTROGEN_RESPONSE_EARLY+0.090
  • PI3K_AKT_MTOR_SIGNALING+0.070
  • FATTY_ACID_METABOLISM+0.050

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
  • INTERFERON_ALPHA_RESPONSE-0.560
  • ALLOGRAFT_REJECTION-0.550
  • ANGIOGENESIS-0.550
  • TNFA_SIGNALING_VIA_NFKB-0.520
  • INFLAMMATORY_RESPONSE-0.490
  • INTERFERON_GAMMA_RESPONSE-0.490
  • IL6_JAK_STAT3_SIGNALING-0.480
  • E2F_TARGETS-0.440
  • KRAS_SIGNALING_UP-0.440

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-MP-A5C7-01A-11R-A262-07
lung-landscapes@6
cohortA20.903
2DRR168589
bladder-landscape@3
0.900
3TCGA-D8-A1JN-01A-11R-A13Q-07
breast-umap@18
C0.878
4SRR8943016
bladder-landscape@3
0.876
5MDT-AP-3207
medullo-epn-umap@date-based
MedMedulloblastoma0.875
6TCGA-D8-A1XC-01A-11R-A14D-07
breast-umap@18
B0.870
7SRR35579848
breast-umap@18
B0.869
8C3L-03721
lung-landscapes@6
cohortA20.868
9MBCProject_0343_T1_RNA
breast-umap@18
B0.862
10SRR8613720
breast-umap@18
C0.861

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 11 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.350Remibrutinib— uncovered
ADIPOGENESIS0.220Inavolisib— uncovered
PEROXISOME0.200Idelalisib— uncovered
BILE_ACID_METABOLISM0.190Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.140Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.140Idelalisib— uncovered
ANDROGEN_RESPONSE0.100Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.090Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.070Inavolisib— uncovered
FATTY_ACID_METABOLISM0.050Inavolisib— uncovered
HEME_METABOLISM0.040Temsirolimus— uncovered